The combination of PD-L1 blocker and PLK1 inhibitor can produce synergistic effect in mice, significantly reduce the tumor burden and prolong the survival period of mice37.The proliferation of tumor cells can be inhibited by inhibiting the expression of PLK1, which may thus be a potential target for cancer therapy38. Here, CD274 is linked to cancer.